BioNTech SE (BNTX) Cash & Equivalents (2018 - 2025)

BioNTech SE (BNTX) has 8 years of Cash & Equivalents data on file, last reported at $11.7 billion in Q4 2025.

• In Q4 2025, Cash & Equivalents rose 12.63% year-over-year to $11.7 billion; the TTM figure through Dec 2025 stood at $11.7 billion (up 12.63% YoY), while the FY2025 annual figure was $11.4 billion, up 9.31% from the prior year.
• Cash & Equivalents held at $11.7 billion in Q4 2025, from $11.8 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1459786.9 billion in Q1 2021 and bottomed at $1.4 billion in Q3 2021.
• A 5-year average of $73093.7 billion and a median of $12.2 billion in 2023 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 631.05% in 2022, down 99.87% in 2022.
• Year by year, Cash & Equivalents stood at $1.9 billion in 2021, then soared by 631.05% to $14.2 billion in 2022, then dropped by 11.35% to $12.5 billion in 2023, then slipped by 16.88% to $10.4 billion in 2024, then grew by 12.63% to $11.7 billion in 2025.
• The last three Cash & Equivalents figures came in at $11.7 billion (Q4 2025), $11.8 billion (Q3 2025), and $11.6 billion (Q2 2025), per Business Quant data.

Peer Comparison